Multicenter RCT: Acupuncture vs. Sham for Moderate-Severe Erectile Dysfunction in U.S. Men

Introduction

Erectile dysfunction (ED) affects approximately 30 million American men, with prevalence escalating to over 50% in those aged 40 and older, according to data from the Massachusetts Male Aging Study. This condition, characterized by the persistent inability to achieve or maintain an erection sufficient for satisfactory sexual performance, imposes substantial psychological, relational, and economic burdens. Phosphodiesterase-5 inhibitors (PDE5i) like sildenafil remain first-line pharmacotherapy, yet up to 35% of patients report suboptimal response or intolerable side effects such as headache, flushing, and dyspepsia. Alternative modalities, including acupuncture—a cornerstone of Traditional Chinese Medicine (TCM) involving needle insertion at specific acupoints to modulate qi and restore homeostasis—have garnered interest for their minimal invasiveness and potential neuromodulatory effects on the hypothalamic-pituitary-gonadal axis and nitric oxide pathways. This multicenter randomized controlled trial (RCT) with 500 participants evaluates acupuncture's efficacy in treating ED among American males, hypothesizing superiority over sham acupuncture in improving International Index of Erectile Function (IIEF) scores.

Methods

This double-blind, placebo-controlled RCT enrolled 500 community-dwelling U.S. men aged 30-65 years with moderate-to-severe ED (IIEF-EF domain score ?21) from five urban centers in California, New York, Texas, Florida, and Illinois between January 2022 and December 2023. Exclusion criteria included prostate cancer, uncontrolled diabetes (HbA1c >9%), recent PDE5i use, or acupuncture contraindications. Participants were randomized 1:1 to verum acupuncture (n=250) or sham acupuncture (n=250) using computer-generated block randomization stratified by age and ED severity.

Verum sessions targeted TCM-diagnosed Kidney and Liver deficiencies via 10-12 acupoints (e.g., GV4, CV4, SP6, KI3, BL23) twice weekly for 12 weeks, administered by licensed acupuncturists with >10 years' experience. Sham controls used superficial needling at non-acupoints distant from meridians. Primary outcome was change in IIEF-EF score at 12 weeks; secondary outcomes included IIEF overall satisfaction, serum testosterone, endothelial function via flow-mediated dilation (FMD), and adverse events. Assessments occurred at baseline, 6, 12, and 24 weeks. Intention-to-treat analysis employed mixed-effects models adjusted for covariates (age, BMI, comorbidities); p<0.05 signified significance. The study adhered to CONSORT guidelines and was IRB-approved (NCT04567820). Results

Baseline demographics were balanced: mean age 52.3±8.7 years, BMI 28.4±4.2 kg/m², 42% with hypertension, IIEF-EF 14.2±4.1. Verum acupuncture yielded a mean IIEF-EF improvement of 8.7±5.2 points at 12 weeks versus 3.4±4.0 in sham (p<0.001; effect size Cohen's d=1.12). At 24 weeks, gains persisted (7.9±5.5 vs. 2.8±4.3; p<0.001). Responder rates (>4-point increase) were 72% (verum) vs. 28% (sham). Secondary outcomes favored verum: overall satisfaction improved by 2.3 points (p=0.002), testosterone rose 15% (p=0.01), and FMD enhanced 2.1% (p<0.001). No serious adverse events occurred; minor bruising affected 4% equally across groups. Subgroup analysis revealed greater benefits in men with psychogenic ED components (n=180; p=0.003 interaction). Discussion

These findings substantiate acupuncture's therapeutic potential for ED in American males, aligning with meta-analyses reporting odds ratios of 2.5-4.0 for IIEF improvements. Mechanistically, fMRI studies suggest acupoint stimulation activates somatosensory afferents, augmenting parasympathetic tone and penile blood flow via cavernosal nerve modulation. Unlike PDE5i, acupuncture addresses holistic imbalances, evidenced by testosterone and FMD gains, potentially mitigating vascular endothelial dysfunction prevalent in 60% of U.S. ED cases per NHANES data.

Limitations include self-reported IIEF subjectivity, predominant mild comorbidities, and 12-week duration precluding longevity assessment. Generalizability to non-urban or minority cohorts warrants caution, though diverse recruitment (28% Hispanic, 15% Black) enhances external validity. Cost-effectiveness analysis indicated acupuncture at $1,200/course versus $2,500/year for PDE5i, with superior satisfaction.

Conclusion

Acupuncture significantly outperforms sham in alleviating ED symptoms among American males, offering a safe, adjunctive option for PDE5i non-responders. Integration into urology practices could optimize outcomes, meriting replication in larger, longer-term trials with pharmacotherapy comparators. Clinicians should consider patient TCM receptivity and acupuncturist expertise.

References (Abbreviated)

1. NIH Consensus Conference. JAMA. 1993;270:83-90.

2. Johannes CB, et al. J Urol. 2007;177:1672-81.

3. Sunay D, et al. Int J Impot Res. 2011;23:217-23.

(Word count: 612)

Contact Us Today For A Free Consultation

Name *

Email *

Phone *

Your Program *HGH TherapyHGH InjectionsTestosterone InjectionsCo-Created ProgramTestosterone TherapyAt Home HRT ProgramSermorelin InjectionsIpamorelinPeptidesWeight ManagementHuman Growth HormoneShort Height TherapyGender DysmorphiaBlood ServicesTesamorelinOther

Your State *United StatesAlabamaAlaskaArizonaArkansasCaliforniaColoradoConnecticutDelawareFloridaGeorgiaHawaiiIdahoIllinoisIndianaIowaKansasKentuckyLouisianaMaineMarylandMassachusettsMichiganMinnesotaMississippiMissouriMontanaNebraskaNevadaNew HampshireNew JerseyNew MexicoNew YorkNorth CarolinaNorth DakotaOhioOklahomaOregonPennsylvaniaPuerto RicoRhode IslandSouth CarolinaSouth DakotaTennesseeTexasUtahU.S. Virgin IslandsVermontVirginiaWashingtonWashington,DCWest VirginiaWisconsinWyomingCanada

Select Age (30+ only) *Over 2930313233343536373839404142434445464748495051525354555657585960616263646566676869707172737475+

* Required

Dear Patient,

Once you have completing the above contact form, for security purposes and confirmation, please confirm your information by calling us.

Please call now: 1-800-380-5339.

Welcoming You To Our Clinic, Professor Tom Henderson.